Pathological Fracture of Multiple Myeloma with CRAB Criteria: A Case Report
Keywords:
Multiple myeloma, CRAB criteria, FractureAbstract
Multiple myeloma (MM) is a malignancy of plasma cells, often preceded by an asymptomatic condition known as the precursor state of monoclonal gammopathy of undetermined significance (MGUS). The diagnosis of multiple myeloma is typically confirmed using the CRAB criteria, which include hypercalcemia, renal impairment characterized by elevated serum urea and creatinine levels, anemia, and bone abnormalities. We report a rare case of multiple myeloma in a 63-year-old male patient who presented with pain in his left hand following a fall against a wall. Clinical and radiological examinations revealed findings consistent with multiple myeloma, with a differential diagnosis including metabolic bone disease and metastatic bone disease
Downloads
References
Sutandyo N, Firna E, Agustina J, Prayogo N, Widjaja L. Clinicopathology Profile and Bone Involvement of Multiple Myeloma Patients in Dharmais National Cancer Hospital, Indonesia. Asian Pacific Journal of Cancer Prevention. 2015 Oct 6;16(15):6261–5.
An ZY, Fu H, He Y, Zhu X, Huang QS, Wu J, et al. Projected Global Trends in Hematological Malignancies: Incidence, Mortality, and Disability-Adjusted Life Years from 2020 to 2030. Blood. 2023 Nov 2;142(Supplement 1):3810–3810. Cowan AJ, Allen C, Barac A, Basaleem H, Bensenor I, Curado MP, et al. Global Burden of Multiple Myeloma. JAMA Oncol. 2018 Sep 1;4(9):1221.
Fazio M, Del Fabro V, Parrinello NL, Allegra A, Markovic U, Botta C, et al. Multiple Myeloma in 2023 Ways: From Trials to Real Life. Current Oncology. 2023 Nov 3;30(11):9710–33.
Cowan AJ, Allen C, Barac A, Basaleem H, Bensenor I, Curado MP, et al. Global Burden of Multiple Myeloma. JAMA Oncol. 2018 Sep 1;4(9):1221.
Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. Journal of Clinical Oncology. 2015 Sep 10;33(26):2863–9.
Palumbo A, Anderson K, Battista SG. Medical Progress Multiple Myeloma.
Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022 Aug 23;97(8):1086–107.
Kumar SK, Rajkumar V, Kyle RA, et al. Multiple myeloma. Nat Rev Dis Primers. 2017;3:17046. DOI: 10.1038/nrdp.2017.46
Gau YC, Yeh TJ, Hsu CM, Hsiao SY, Hsiao HH. Pathogenesis and Treatment of Myeloma-Related Bone Disease. Int J Mol Sci. 2022;23(6):3112. Published 2022 Mar 14. doi:10.3390/ijms23063112
Teramachi J, Miki H, Nakamura S, Hiasa M, Harada T, Abe M. Myeloma bone disease: pathogenesis and management in the era of new anti-myeloma agents. J Bone Miner Metab. 2023;41(3):388-403. doi:10.1007/s00774-023-01403-4
Facon T, Kumar S, Plesner T, et al. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. N Engl J Med. 2019;380(22):2104-2115. DOI: 10.1056/NEJMoa1817249
Annadatha A, Acharya S, Shukla S, Bhawane A, Varma A, Andhale A. Multiple Myeloma presenting as Hypercalcemic Crisis: A case report. Medical Science. 2020;24(105),3148-3152
Costa LJ, Chhabra S, Godby KN, et al. Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myeloma (NDMM). Blood. 2019;134(Supplement_1):860. DOI: 10.1182/blood-2019-123170
Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2019;380(18):1726-1737. DOI: 10.1056/NEJMoa1817226
Published
How to Cite
Issue
Section
Copyright (c) 2024 Habib Burahman, Silvia Laelatus Sifa, Tabitha Puspaning Asmara
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
